Inventor · disambiguated record
Sandip Panicker
Also filed as: PANICKER SANDIP
23 granted patents·15 pending applications·161 citations·filing 2013–2025
96Inventor score
Files withBIOVERATIV USA INC20TRUE NORTH THERAPEUTICS INC8ELECTRA THERAPEUTICS INC4VEGA THERAPEUTICS INC3GENZYME CORP1
Top patents by PatentIndex Score
38 records- 0197US11246926B2Polynucleotides encoding anti-C1s antibodiesBIOVERATIV USA INC·Filed 2020·Granted Feb 15, 2022·4 cites·11 claims
- 0296US9206259B2Methods of inhibiting complement C4 activation with anti-complement C1S antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Dec 8, 2015·15 cites·13 claims
- 0396US8945562B2Anti-complement C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2013·Granted Feb 3, 2015·24 cites·47 claims
- 0496US8877197B2Anti-complement C1sTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Nov 4, 2014·22 cites·25 claims
- 0594US10729767B2Humanized anti-C1s antibodies and methods of inhibiting C1s cleavageBIOVERATIV USA INC·Filed 2016·Granted Aug 4, 2020·9 cites·32 claims
- 0694US9562092B2Methods of inhibiting complement C4 activation with anti-complement C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·10 cites·13 claims
- 0794US9512233B2Anti-complement C1s antibodies and methods of inhibiting complement C1s activityTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Dec 6, 2016·12 cites·41 claims
- 0894US9074004B2Methods of inhibiting activation of complement component C4 with anti-C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·15 cites·13 claims
- 0994US9074003B2Methods of inhibiting activation of complement component C4 with anti-C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·15 cites·30 claims
- 1093US12215169B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Feb 4, 2025·1 cites·21 claims
- 1193US10450382B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 22, 2019·8 cites·9 claims
- 1292US12145999B2Protein S antibodies, methods of making and uses thereofVEGA THERAPEUTICS INC·Filed 2023·Granted Nov 19, 2024·2 cites·25 claims
- 1392US2025263503A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 1491US9562106B2Anti-complement C1s antibodies and methods of inhibiting complement C1s activityTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·8 cites·31 claims
- 1590US10457745B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 29, 2019·6 cites·10 claims
- 1689US12187797B2SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereofELECTRA THERAPEUTICS INC·Filed 2024·Granted Jan 7, 2025·4 cites·29 claims
- 1786US10934347B2Anti-complement factor BB antibodies and uses thereofBIOVERATIV USA INC·Filed 2017·Granted Mar 2, 2021·4 cites·15 claims
- 1883US12391750B2Anti-C1S antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2023·Granted Aug 19, 2025·0 cites·16 claims
- 1982US12240917B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Mar 4, 2025·0 cites·13 claims
- 2082US2025188192A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2025·Application pending·0 cites
- 2179US12421320B2Protein S antibodies, methods of making and uses thereofVEGA THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·0 cites·21 claims
- 2279US11192944B2Methods of inducing complement activityBIOVERATIV USA INC·Filed 2018·Granted Dec 7, 2021·2 cites·13 claims
- 2378US2025295768A1Methods of treating autoimmune and alloimmune disordersBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 2477US2025197492A1Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereofELECTRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2575US2024228599A1Anti-complement factor bb antibodies and uses thereofGENZYME CORP·Filed 2023·Application pending·0 cites
- 2674US2023218753A1Humanized anti-c1s antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2022·Application pending·0 cites
- 2772US2020079875A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2019·Application pending·0 cites
- 2870US2025145696A1Methods for treating complement-mediated diseases and disordersBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 2969US11851482B2Anti-complement factor Bb antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Dec 26, 2023·0 cites·20 claims
- 3068US2020079876A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2019·Application pending·0 cites
- 3167US12441810B2Protein S antibodies, methods of making and uses thereofVEGA THERAPEUTICS INC·Filed 2021·Granted Oct 14, 2025·0 cites·20 claims
- 3266US12503508B2SIRP alpha, SIRP beta 1, and SIRP gamma antibodies and uses thereofELECTRA THERAPEUTICS INC·Filed 2021·Granted Dec 23, 2025·0 cites·44 claims
- 3366US2022249664A1Methods of treating autoimmune and alloimmune disordersBIOVERATIV USA INC·Filed 2021·Application pending·0 cites
- 3459US2024400677A1Sirp gamma antibodies and uses thereofELECTRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3554US2020048332A1Anti-c1s antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2017·Application pending·0 cites
- 3648US2021115116A1Methods for treating complement-mediated diseases and disordersBIOVERATIV USA INC·Filed 2018·Application pending·0 cites
- 3741US2018169240A1Methods of treating autoimmune and alloimmune disordersPARRY GRAHAM·Filed 2016·Application pending·0 cites
- 3839US2016009772A1Cell penetrating peptides which bind irf5HOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sandip Panicker files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →